Alphatec Holdings, a leader in innovative spine surgery solutions, and Theradaptive, a clinical-stage regenerative medicine company, has announced a definitive strategic partnership that could redefine spinal fusion treatments.
At the same time, Theradaptive launched a Series B investment round to accelerate the global expansion of its proprietary protein-engineering platform.
Under the agreement, ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications. The deal includes a mix of upfront and milestone payments, plus a perpetual royalty structure, marking a landmark collaboration in regenerative medicine for the spine industry.
OsteoAdapt leverages Theradaptive’s AMP2 protein technology and has received three FDA Breakthrough Device Designations, highlighting its potential to address critical unmet needs in bone regeneration. The product is also under FDA PMA review.
“The partnership with Theradaptive represents an important milestone in the continued evolution of ATEC's procedural ecosystem,” said Pat Miles, Chairman and CEO of ATEC.
“We have built a strong foundation of procedural spine solutions through informatics, imaging, navigation, and instrumentation, and the industry has long sought biologic solutions that can further enhance fusion outcomes in a meaningful way. OsteoAdapt is that solution. By integrating this breakthrough technology into our Organic Innovation Machine, we are poised to set a new standard for clinical distinction in spine.”
Theradaptive’s Series B round aims to fund the completion of clinical trials and scale its protein-engineering platform in tandem with the ATEC partnership. The financing will support the OASIS Pivotal trial in spinal fusion and expand manufacturing for commercialization.
“In ATEC, we have found the ideal partner to bring this revolutionary technology to the patients who need it most,” said Luis Alvarez, Founder and CEO of Theradaptive. “The synergy between our engineered protein platform and ATEC's commercial reach, coupled with the initiation of our Series B round, ensures that we are capitalized to deliver a new era of regenerative medicine.”
The U.S. spine surgery market exceeds $10 billion annually, with biologics representing over $2 billion. OsteoAdapt’s targeted approach aims to disrupt traditional allograft and synthetic alternatives, with sustained sales growth through ATEC’s commercial network expected to maximize market penetration and deliver ongoing royalties to Theradaptive.
